Solid tumor/s, Cancer, Ovarian cancer, Breast cancer, Endometrial cancer
NXTCNextCure IncCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for LNCB74 (B7-H4 ADC) in Solid tumor/s, Cancer, Ovarian cancer, Breast cancer, Endometrial cancer. The expected timing is based on the latest available company guidance and may change.
Collab w/ LegoChem Biosciences. 12/10/24- IND application accepted. 1/5/25- FDA accepted amendment adding higher dose cohorts; Ph1 PoC data in H1 2026. 01/23/26:- Higher-dose Ph1 cohorts enrolling including adenoid cystic carcinoma; PoC delayed; trial progress update in H2 2026. 03/05/26:- Higher-dose Ph1 cohort enrollment underway; update from NCT06774963 planned H2 2026. 05/07/26:- Ongoing Ph1 NCT06774963 enrollment; plan patient backfilling for dose levels; trial progress update reiterated for H2 2026. 08/06/26:- LigaChem became sole developer; ongoing Ph1 operations continue, with H2 2026 update unchanged.
Verification
Confirm timing and program details against the company announcement or filing.